ID   SUM229PE
AC   CVCL_5594
SY   SUM-229PE; SUM 229PE; SUM-229; SUM 229; SUM229; 229PE
DR   BTO; BTO:0005479
DR   CLO; CLO_0009921
DR   EFO; EFO_0006762
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03471035
DR   cancercelllines; CVCL_5594
DR   Cell_Model_Passport; SIDM01461
DR   Cosmic; 904393
DR   Cosmic; 997923
DR   Cosmic; 1046949
DR   Cosmic; 1287930
DR   Cosmic; 1289416
DR   Cosmic; 1460243
DR   Cosmic; 1479523
DR   DepMap; ACH-001394
DR   EGA; EGAS00001000610
DR   GEO; GSM421892
DR   GEO; GSM1172996
DR   GEO; GSM1172902
DR   IARC_TP53; 24363
DR   LINCS_HMS; 51086
DR   LINCS_LDP; LCL-2065
DR   PharmacoDB; SUM229PE_1512_2019
DR   PRIDE; PXD005295
DR   SLKBase; 295
DR   Wikidata; Q54970849
RX   PubMed=10424408;
RX   PubMed=10604729;
RX   PubMed=10969801;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=19593635;
RX   PubMed=21778573;
RX   PubMed=23401782;
RX   PubMed=23601657;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=28287265;
RX   PubMed=32715085;
WW   https://bioivt.com/sum-breast-cancer-cell-lines/
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Problematic cell line: Partially misidentified. For a period of time Asterand (now BioIVT) mistakenly distributed SUM149PT (Cellosaurus=CVCL_3422) under the designation of SUM229PE. This leads to the publication of a STR profile (PubMed=25877200) which was almost identical to that of SUM149PT.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: GrayJW breast cancer cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00548.
CC   Doubling time: 42.27 hours (GrayJW panel).
CC   HLA typing: A*02:01,11:01; B*40:02,44:02; C*02:02,03:04; DQB1*05:01,05:01; DRB1*01:01,15:01 (PubMed=25960936).
CC   HLA typing: A*68:01,68:01; B*53:02,78:01; C*06:02,16:01 (PubMed=26589293).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=19593635; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=16541312; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: miRNA expression profiling.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): BioIVT/Asterand
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D16S539: 11,13
ST   D5S818: 9,12
ST   D7S820: 8,9
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 18,19
DI   NCIt; C4872; Breast carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   PubMed=10424408; DOI=10.1023/A:1006135331912;
RA   Ignatoski K.M.W., Ethier S.P.;
RT   "Constitutive activation of pp125fak in newly isolated human breast
RT   cancer cell lines.";
RL   Breast Cancer Res. Treat. 54:173-182(1999).
//
RX   PubMed=10604729; DOI=10.1038/sj.bjc.6695007;
RA   Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A.,
RA   Kallioniemi O.-P., Ethier S.P.;
RT   "Molecular cytogenetic analysis of 11 new breast cancer cell lines.";
RL   Br. J. Cancer 81:1328-1334(1999).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=21778573; DOI=10.3233/BD-2010-0307;
RA   Chavez K.J., Garimella S.V., Lipkowitz S.;
RT   "Triple negative breast cancer cell lines: one tool in the search for
RT   better treatment of triple negative breast cancer.";
RL   Breast Dis. 32:35-48(2010).
//
RX   PubMed=23401782; DOI=10.1155/2013/872743;
RA   Barnabas N., Cohen D.;
RT   "Phenotypic and molecular characterization of MCF10DCIS and SUM breast
RT   cancer cell lines.";
RL   Int. J. Breast Cancer 2013:872743.1-872743.16(2013).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
//
RX   PubMed=32715085; DOI=10.1038/s41523-020-0173-z;
RA   Ethier S.P., Guest S.T., Garrett-Mayer E., Armeson K., Wilson R.C.,
RA   Duchinski K., Couch D., Gray J.W., Kappler C.S.;
RT   "Development and implementation of the SUM breast cancer cell line
RT   functional genomics knowledge base.";
RL   NPJ Breast Cancer 6:30.1-30.14(2020).
//